Compare NXL & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXL | NOTV |
|---|---|---|
| Founded | 2010 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 19.7M |
| IPO Year | 2022 | 1997 |
| Metric | NXL | NOTV |
|---|---|---|
| Price | $0.61 | $0.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $3.00 |
| AVG Volume (30 Days) | 156.8K | ★ 416.1K |
| Earning Date | 03-13-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $156,931.00 | ★ $513,024,000.00 |
| Revenue This Year | $38.28 | $6.49 |
| Revenue Next Year | $185.71 | $4.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $0.54 | $0.47 |
| 52 Week High | $3.87 | $4.80 |
| Indicator | NXL | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 34.66 |
| Support Level | $0.58 | $0.53 |
| Resistance Level | $0.77 | $0.59 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 9.09 | 8.87 |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.